Conclusions & Recommendations
24.1.3 - General Recommendations
Conclusion/Recommendation:
include regional prevalence maps in the TEC book, behind each regional tab, so that the cross-border situation can be taken into account when reviewing applications
Action:
These regional prevalence maps will be included beginning TEC 27
TEC 24
2021
TEC meeting management, COVID
24.1.4 - General Recommendations
Conclusion/Recommendation:
add the definition of coverage to the ‘cheat sheet’
Action:
The definition of Zithromax® coverage has been edited and is included on the TEC cheat sheet
TEC 24
2021
TEC meeting management, coverage
24.1.5 - General Recommendations
Conclusion/Recommendation:
add more details regarding requests for Zithromax® post-TT surgery (funders and implementing partners)
Action:
This information is being collected in the 2023 Zithromax® for TT-Surgery application form.
TEC 24
2021
TEC meeting management, trichiasis
24.10.1 - Peru
Conclusion/Recommendation:
TEC notes that despite several consecutive years of approving the Zithromax® request, MDA has not yet started. TEC recommends that ITI continue to monitor this situation closely and follow-up to ensure the MOU is signed.
Action:
ITI presented on these challenges in September 2021 during the PAHO Americas meetings and continues to discuss the challenges with PAHO and the MOH in Peru. ITI and PAHO hope that an agreement to ship Zithromax® via PAHO will replace the highly bureaucratic MOU process, which has been stalled for several years.
TEC 24
2021
Americas
Peru
recommendations for ITI management
24.11.1 - DRC
Conclusion/Recommendation:
TEC recognizes that DRC has the second highest population at-risk of trachoma in the world and is at risk of losing momentum of the existing progress, putting more people at risk of trachoma if adequate funding and technical support cannot be identified.
Action:
No action required
TEC 24
2021
Africa - Central/Southern
DRC
funding
24.11.2 - DRC
Conclusion/Recommendation:
TEC encourages the MOH to access available funding from ESPEN for trachoma activities where there are gaps and encourages other donors to further support the MOH in achieving elimination.
Action:
This recommendation has been shared with the country
TEC 24
2021
Africa - Central/Southern
DRC
funding
24.12.1 - Mozambique
Conclusion/Recommendation:
TEC recommends that the MOH and partners consider collecting infection data in districts with TF1-9 just above 5% at TIS and TSS in several districts. This may be a sign of lagging TF rather than a need for additional MDA or recrudescence, and infection data would provide a more complete picture of trachoma in those districts.
Action:
This recommendation has been shared with the country. Following the TEC guidance that arose from the December 2021 WHO Informal Consultation, the national program has proposed a modified treatment and monitoring strategy.
TEC 24
2021
Africa - Central/Southern
Mozambique
alternative indicators (Ct, serology), end game, research
24.12.2 - Mozambique
Conclusion/Recommendation:
TEC notes the security challenges in Cabo Delgado and the threat they pose to elimination in Mozambique. TEC recommends that ITI work with countries to document population disruptions and the potential impact of IDPs/refugees on progress towards elimination, and to propose ways to assist national decision-making on how to account for changing population numbers for future MDAs and/or surveys.
Action:
The national program visited Cabo Delgado in March and is exploring the possibility of completing impact surveys in four southern districts in 2022. Additionally, IDPs from Cabo Delgado were included in the 2021 MDAs in Nampula and additional Zithromax® has also been allocated for their inclusion in the 2022 MDAs.
TEC 24
2021
Africa - Central/Southern
Mozambique
insecurity, special populations
24.13.1 - Zambia
Conclusion/Recommendation:
TEC recognizes the hardship placed on Zambia’s trachoma program from the budget cuts by the UK government’s Foreign, Commonwealth & Development Office (FCDO), leaving a funding gap for 2021 interventions (including MDA in three districts, trachoma surveillance surveys in 17 districts, and one trachoma impact survey) and 2022 interventions (MDA in seven districts and eight trachoma impact surveys).
Action:
The feedback has been shared with the MOH and implementing partners. BMGF and ITI are supporting MDAs and trachoma prevalence surveys through June 2023.
TEC 24
2021
Africa - Central/Southern
Zambia
funding
24.14.1 - Cameroon
Conclusion/Recommendation:
TEC recommends that ITI follow up to better understand the situation in refugee camps in the Lake Chad Basin and whether addressing these populations is included in the national program’s plans.
Action:
This recommendation has been shared with the country; however, this situation also applies to Niger, Nigeria, and Chad. The issue will be raised for inclusion on the agenda at the next RAFET meeting.
TEC 24
2021
Africa - West
Cameroon
special populations, recommendations for ITI management